Biotechnology

Akari Therap

Akari Therap released FY2025 annual earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -20.5536 (forecast USD -10.6666)

Akari Therap released FY2025 Q4 earnings on March 30 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.9052 (forecast USD -1.8)

Akari Therapeutics and WuXi XDC Collaborate on AKTX-101 GMP Production

Akari Therap released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -7.8375 (forecast USD -4.8)

Akari Therap released FY2025 9 Months Earnings on November 13 (EST), with actual revenue of USD 0 and EPS of USD -15.6758

Akari Therapeutics Submits Two Patent Applications to USPTO

Jason McCarthy Reiterates Buy Rating on Akari Therapeutics

Akari Therap released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -7.6234

Akari Therap released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.4084 (forecast USD -4.4)

Akari Therapeutics CEO Acquires Company Stocks

Akari Therapeutics Obtains PH1 Antibody-Drug Conjugate Patent in India

Akari Therapeutics Releases Video Introducing New Oncology Business Development Leader

Akari Therap released FY2025 Q1 earnings on May 14, 2025 (EST) with actual revenue of USD 0 and EPS of USD -5.4297

Akari Therapeutics Sees Sufficient Cash to End September 2025

Akari Therap released FY2024 earnings on April 15 (EST), actual revenue USD 0, actual EPS USD -66.2793 (forecast EPS USD -136)

Akari Therap released FY2024 Q4 earnings on April 15 (EST), actual revenue USD 0 (forecast USD --), actual EPS USD -7.774 (forecast USD -40)

Akari Therap released FY2024 Q3 earnings on November 19 (EST), actual revenue USD 0 (forecast USD --), actual EPS USD -9.4972 (forecast USD -24)

Akari Therap released FY2024 9 Months earnings on November 19, 2024 (EST), actual revenue USD 0, actual EPS USD -74.6953

Akari Therap released FY2024 Semi-Annual Earnings on August 19 (EST), with actual revenue of USD 0 and EPS of USD -65.0314

Akari Therap released FY2024 Q2 earnings on August 19 (EST), actual revenue USD 0 (forecast USD --), actual EPS USD -32.0994 (forecast USD -40)

Neuberger Berman Income Funds - Neuberger High Yield Strategies Fund Inc.

Snail

Mint Incorporation

Arrive AI

Avanos Medical

Ambitions Enterprise

ESH ACQUISITION CORP COM USD0.0001 CL A (S/R 13/06/2028)

Mega Fortune

Tradr 2X Long BE Daily ETF

Perfect Moment

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Akari Therap(AKTX.US)

Akari Therap Stock Performance Chart